0.7109
price up icon0.84%   0.0059
after-market After Hours: .71 -0.0009 -0.13%
loading
Neumora Therapeutics Inc stock is traded at $0.7109, with a volume of 1.53M. It is up +0.84% in the last 24 hours and down -37.09% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$0.705
Open:
$0.7303
24h Volume:
1.53M
Relative Volume:
0.98
Market Cap:
$102.05M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.2805
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
+12.84%
1M Performance:
-37.09%
6M Performance:
-94.66%
1Y Performance:
-93.10%
1-Day Range:
Value
$0.6925
$0.805
1-Week Range:
Value
$0.627
$0.805
52-Week Range:
Value
$0.6211
$17.19

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name
Name
Neumora Therapeutics Inc
Name
Phone
(857) 760-0900
Name
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Name
Employee
110
Name
Twitter
Name
Next Earnings Date
2025-03-03
Name
Latest SEC Filings
Name
NMRA's Discussions on Twitter

Compare NMRA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NMRA
Neumora Therapeutics Inc
0.7109 102.05M 0 -274.18M -198.33M -2.5346
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.42 124.91B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
587.85 60.05B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
594.65 35.88B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.97 29.83B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.13 24.58B 3.81B -644.79M -669.77M -6.24

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-02-25 Downgrade BofA Securities Buy → Underperform
Mar-10-25 Downgrade William Blair Outperform → Mkt Perform
Mar-07-25 Downgrade Guggenheim Buy → Neutral
Mar-07-25 Downgrade Stifel Buy → Hold
Jan-02-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-05-24 Downgrade JP Morgan Overweight → Neutral
Oct-01-24 Initiated H.C. Wainwright Buy
Jul-22-24 Initiated Needham Buy
Jul-08-24 Initiated Mizuho Outperform
Dec-12-23 Initiated Deutsche Bank Hold
Oct-10-23 Initiated BofA Securities Buy
Oct-10-23 Initiated Guggenheim Buy
Oct-10-23 Initiated JP Morgan Overweight
Oct-10-23 Initiated RBC Capital Mkts Outperform
Oct-10-23 Initiated Stifel Buy
Oct-10-23 Initiated William Blair Outperform
View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

pulisher
12:15 PM

NMRA’s valuation metrics: A comprehensive analysis - uspostnews.com

12:15 PM
pulisher
04:55 AM

Capital International Investors Raises Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

04:55 AM
pulisher
Apr 22, 2025

Former Neumora CEO to lead Galapagos spinout - BioPharma Dive

Apr 22, 2025
pulisher
Apr 17, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus PT from Analysts - MarketBeat

Apr 17, 2025
pulisher
Apr 17, 2025

Alliancebernstein L.P. Sells 22,930 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

Apr 17, 2025
pulisher
Apr 13, 2025

Vanguard Group Inc. Purchases 195,142 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Neumora Therapeutics' (NMRA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Apr 12, 2025
pulisher
Apr 12, 2025

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Hold” by Analysts - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World

Apr 12, 2025
pulisher
Apr 10, 2025

KLP Kapitalforvaltning AS Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

Apr 10, 2025
pulisher
Apr 09, 2025

Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating - TipRanks

Apr 09, 2025
pulisher
Apr 07, 2025

Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 07, 2025

NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Apr 07, 2025
pulisher
Apr 07, 2025

Neumora Therapeutics, Inc. Investors: Please contact the - GlobeNewswire

Apr 07, 2025
pulisher
Apr 07, 2025

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion. - TradingView

Apr 07, 2025
pulisher
Apr 07, 2025

Neumora Therapeutics, Inc. (NASDAQ: NMRA) Investor Alert: Deadline in Lawsuit on April 7, 2025 - openPR.com

Apr 07, 2025
pulisher
Apr 07, 2025

Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire

Apr 07, 2025
pulisher
Apr 07, 2025

Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky about Pending Class ActionNMRA - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 07, 2025

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

Apr 07, 2025
pulisher
Apr 07, 2025

Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - PR Newswire

Apr 07, 2025
pulisher
Apr 06, 2025

NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, - GlobeNewswire

Apr 06, 2025
pulisher
Apr 06, 2025

NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. - Bluefield Daily Telegraph

Apr 06, 2025
pulisher
Apr 06, 2025

NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Fir - TradingView

Apr 06, 2025
pulisher
Apr 06, 2025

NMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire

Apr 06, 2025
pulisher
Apr 06, 2025

Faruqi & Faruqi Reminds Neumora Therapeutics Investors of - GlobeNewswire

Apr 06, 2025
pulisher
Apr 06, 2025

Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - Morningstar

Apr 06, 2025
pulisher
Apr 05, 2025

Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

Apr 05, 2025
pulisher
Apr 05, 2025

NMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit - The Malaysian Reserve

Apr 05, 2025
pulisher
Apr 04, 2025

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm - PR Newswire

Apr 04, 2025
pulisher
Apr 04, 2025

Shareholders That Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class ActionNMRA - ACCESS Newswire

Apr 04, 2025
pulisher
Apr 04, 2025

Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora ... - Bluefield Daily Telegraph

Apr 04, 2025
pulisher
Apr 04, 2025

Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA) - GlobeNewswire

Apr 04, 2025
pulisher
Apr 04, 2025

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Neumora Therapeutics, Inc. to Contact the Firm Today! - markets.businessinsider.com

Apr 04, 2025
pulisher
Apr 04, 2025

Neumora Therapeutics' (NMRA) "Underperform" Rating Reaffirmed at Bank of America - MarketBeat

Apr 04, 2025
pulisher
Apr 04, 2025

Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of - GuruFocus

Apr 04, 2025
pulisher
Apr 04, 2025

Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Neumora Therapeutics (NASDAQ:NMRA) Earns “Underperform” Rating from Bank of America - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Shareholders that Lost Money on Neumora Therapeutics, Inc. (NMRA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

Apr 03, 2025
pulisher
Apr 03, 2025

NMRA Investors Have Opportunity to Lead Neumora Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire

Apr 03, 2025
pulisher
Apr 03, 2025

NMRA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Fir - TradingView

Apr 03, 2025
pulisher
Apr 03, 2025

NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Neumora Therapeutics, Inc. to Contact the Firm Today! - markets.businessinsider.com

Apr 03, 2025
pulisher
Apr 03, 2025

Neumora Therapeutics stock hits 52-week low at $0.88 - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Shareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - Morningstar

Apr 03, 2025
pulisher
Apr 02, 2025

NMRA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

NMRA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit - GlobeNewswire Inc.

Apr 02, 2025
pulisher
Apr 02, 2025

2025-04-02 | Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class ActionNMRA | NDAQ:NMRA | Press Release - Stockhouse

Apr 02, 2025
pulisher
Apr 02, 2025

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - Morningstar

Apr 02, 2025
pulisher
Apr 02, 2025

NMRA Investors Have Final Opportunity to Lead Neumora Therapeuti - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

NMRA Investors Have Final Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study - TipRanks

Apr 02, 2025

Neumora Therapeutics Inc Stock (NMRA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.13
price down icon 0.69%
$70.80
price down icon 0.62%
$31.69
price down icon 1.55%
$33.23
price up icon 21.50%
$114.83
price up icon 9.70%
biotechnology ONC
$249.13
price down icon 1.44%
Cap:     |  Volume (24h):